Target of this antibody:
Alternative names of antibody target:
BMF, FLJ00065, Bcl-2-modifying factor
Bmf (for Bcl-2-modifying factor) is a novel BH3-only protein recently identified in human and mouse. The BH3 domain in Bmf is required for both binding to Bcl-2 proteins and for triggering apoptosis. In healthy cells, Bmf associates with the dynein light chain 2 (DLC2) component of the myosin V motors and is sequestered by the cell's actin cytoskeleton. Disruption of the actin cytoskeleton, either by depolymerization of actin filaments or by detachment of cells from the extracellular matrix, triggers release and activation of Bmf, initiating the downstream apoptosis program.
Clonality of antibody:
This antibody reacts with:
Human, mouse, rat
Synthetic peptide surrounding amino acid 9 of human BMF
Concentration of antibody:
Form of antibody:
Formulation of this antibody:
100 µg (0.5 mg/ml) affinity purified rabbit anti-BMF polyclonal antibody in phosphate-buffered saline (PBS) containing 30% glycerol, 0.5% BSA, and 0.01% thimerosal.
This antibody has been succesfully tested for use in following methods:
Western blot, Immunohistochemistry
Western blotting (0.5-4 µg/ml) and Immunohistochemistry (5 µg/ml). However, the optimal conditions should be determined individually. The antibody recognizes ~28 kDa BMF in sample from human, mouse and rat origins. Reactivity to other species has not been tested.
Shelf time: 12 months in temp.: -20 deg.C
How to handle this antibody:
The antibody solution should be gently mixed before use.
This antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.
antibody to-Bcl2 modifying factor
Alternative to gene target
Bcl2 modifying factor, BMF and IDBG-6070 and ENSG00000104081 and 90427, protein binding, Plasma membranes, Bmf and IDBG-198160 and ENSMUSG00000040093 and 171543, BMF and IDBG-646206 and ENSBTAG00000012180 and 541141